Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tulisokibart in moderately to severely active Crohn's disease
NL-OMON61003Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tulisokibart in Crohn's disease, sponsored by Merck & Co.. Started Sep 2025; status: recruiting.
02
Drugs
tulisokibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON61003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61003.